PHARMO Institute Seroquel Safety Study - PHARMO II
Study identifier:D1443L00085
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Seroquel Safety Study
Medical condition
schizophrenia
Phase
-
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
18325
Study type
Observational
Age
18 Years +
Date
Study Start Date: 01 Sept 2010
Primary Completion Date: 01 Nov 2010
Study Completion Date: 01 Nov 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
PHARMO Institute for Drug Outcomes Research
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Quetiapine Quetipine users | - |
| All other atypical antipsychotics All other atypical antipsychotics users | - |
| Risperidone Risperidone users | - |
| Olanzapine Olanzapine users | - |
Contacts
Investigators
Principal Investigator
Edith Heintjes
PHARMO Institute for Drug Outcomes Research
